Company intelligence / Profile preview

CerRx

Lubbock, Texas, United Statessystemsoncology.com ↗

Ownership: Private
Development stage: Phase 1

Overview

CerRx is developing anticancer drugs, with their flagship product being an intravenous emulsion. Their pipeline includes Safingol/Fenretinide combination therapy which is in clinical trials for treating neoplasms[2].

Therapeutic areas: Oncology
Modalities: Small molecule drugs
Industry: Biotech

Drug pipeline

2 assets

fenretinide

Phase 1

Indications: T-cell lymphoma, Esophageal adenocarcinoma

1 more asset in the full pipeline.

Request access →

Partnerships

John Wayne Cancer InstituteChildren's Hospital Los AngelesNational Institutes of Health (NIH)[4]

Beyond the preview

Go deeper on CerRx.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CerRx.

Explore the full profile